The U.S. Food and Drug Administration approved
a new drug Thursday that’s been shown to stop migraines before they begin. It’s called Aimovig, and it’s the first FDA-approved
preventive migraine treatment in a new class of drugs that works by blocking a molecule
that’s believed to be involved in migraine attacks. Users inject themselves with the medication
once a month via a device that resembles an insulin pen. And experts say it could be a game changer
for the millions of people who suffer from migraines. As one migraine specialist told The New York
Times: Aimovig is expected to be available to patients
within a week. The U.S. list price for the drug is $575 per
month, or $6,900 per year. But as NBC notes, the FDA’s seal of approval
means the drug could be available with a prescription soon, and health insurance could help shoulder
the cost.

3 thoughts on “FDA approves new drug to prevent migraines”

Leave a Reply

Your email address will not be published. Required fields are marked *